Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108.
Stearns V, ONeill A, Schneider BP, Skaar TC, Liu MC, Lohrisch C, Goetz MP, Vallejos CS, Sparano JA, Villa D, Silverman P, Cheema PS, Moore DF Jr, Sledge GW Jr. Stearns V, et al. Among authors: moore df jr. Breast Cancer Res Treat. 2024 Oct 21. doi: 10.1007/s10549-024-07519-z. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39432161
Clinical Utility of Genomic Recurrence Risk Stratification in Early, Hormone-Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Real-World Experience.
Choucair K, Page SJ, Mattar BI, Dakhil CS, Nabbout NH, Deutsch JM, Truong QV, Truong PV, Moore DF Jr, Cannon MW, Kallail KJ, Moore JA, Dakhil SR, Diab R, Kamran S, Reddy PS. Choucair K, et al. Among authors: moore df jr. Clin Breast Cancer. 2023 Feb;23(2):155-161. doi: 10.1016/j.clbc.2022.11.005. Epub 2022 Nov 23. Clin Breast Cancer. 2023. PMID: 36566135
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.
Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF Jr, Lao C, Faller BA, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, Grossmann KF, Ribas A. Algazi AP, et al. Among authors: moore df jr. Nat Med. 2020 Oct;26(10):1564-1568. doi: 10.1038/s41591-020-1060-8. Epub 2020 Oct 5. Nat Med. 2020. PMID: 33020646 Free PMC article. Clinical Trial.
Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.
Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF Jr, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY; Alliance for Clinical Trials in Oncology and ABTC. Galanis E, et al. Among authors: moore df jr. Neuro Oncol. 2018 Mar 27;20(4):546-556. doi: 10.1093/neuonc/nox161. Neuro Oncol. 2018. PMID: 29016887 Free PMC article. Clinical Trial.
Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU).
Witzig TE, Johnston PB, LaPlant BR, Kurtin PJ, Pederson LD, Moore DF Jr, Nabbout NH, Nikcevich DA, Rowland KM, Grothey A. Witzig TE, et al. Among authors: moore df jr. Am J Hematol. 2017 Oct;92(10):1004-1010. doi: 10.1002/ajh.24824. Epub 2017 Aug 17. Am J Hematol. 2017. PMID: 28614905 Free article. Clinical Trial.
Nausea and disturbed sleep as predictors of cancer-related fatigue in breast cancer patients: a multicenter NCORP study.
Peoples AR, Roscoe JA, Block RC, Heckler CE, Ryan JL, Mustian KM, Janelsins MC, Peppone LJ, Moore DF Jr, Coles C, Hoelzer KL, Morrow GR, Dozier AM. Peoples AR, et al. Among authors: moore df jr. Support Care Cancer. 2017 Apr;25(4):1271-1278. doi: 10.1007/s00520-016-3520-8. Epub 2016 Dec 20. Support Care Cancer. 2017. PMID: 27995318 Free PMC article.
Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.
Till BG, Li H, Bernstein SH, Fisher RI, Burack WR, Rimsza LM, Floyd JD, DaSilva MA, Moore DF Jr, Pozdnyakova O, Smith SM, LeBlanc M, Friedberg JW. Till BG, et al. Among authors: moore df jr. Br J Haematol. 2016 Jan;172(2):208-18. doi: 10.1111/bjh.13818. Epub 2015 Oct 22. Br J Haematol. 2016. PMID: 26492567 Free PMC article. Clinical Trial.
59 results